HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106).

AbstractOBJECTIVE:
Owing to the risks of serious and sustained toxicity, anticancer drugs such as cisplatin and irinotecan cannot be readily administered to patients with gastric cancer and severe peritoneal metastasis. Therefore, a standard chemotherapy regimen has yet to be established for these types of patients. This randomized study investigated the utility of sequential methotrexate and 5-fluorouracil therapy vs. 5-fluorouracil continuous infusion for gastric cancer with peritoneal metastasis.
METHODS:
Eligible patients had radiologically confirmed peritoneal metastasis with intestinal stenosis, peritoneal tumor or ascites. Treatment with 5-fluorouracil continuous infusion (800 mg/m(2)/day, ci, d1-5, q4w) or methotrexate and 5-fluorouracil therapy (methotrexate, 100 mg/m(2), bolus infusion, followed 3 h later by 5-fluorouracil, 600 mg/m(2), bolus infusion, with leucovorin rescue, q1w) was continued until disease progression or unacceptable toxicity. The projected sample size was 236, providing 80% power to detect a 40% increase in median overall survival in methotrexate and 5-fluorouracil therapy with a one-sided α of 0.05.
RESULTS:
All 237 randomized patients were included in the primary analysis. The methotrexate and 5-fluorouracil therapy arm was not superior to the 5-fluorouracil continuous infusion arm (median survival time, 9.4 months in the 5-fluorouracil continuous infusion arm, 10.6 months in the methotrexate and 5-fluorouracil therapy arm; hazard ratio, 0.94; 95% confidence interval, 0.72-1.22; one-sided P = 0.31). Frequencies of Grade 3 or higher neutropenia, Grade 3 or higher anorexia and treatment-related deaths were 0.9, 27.4 and 1.7%, respectively, in the 5-fluorouracil continuous infusion arm, and 31.9, 33.6 and 0.9%, respectively, in the methotrexate and 5-fluorouracil therapy arm.
CONCLUSIONS:
Methotrexate and 5-fluorouracil therapy is not suitable for use as standard therapy for advanced gastric cancer with peritoneal metastasis.
AuthorsKuniaki Shirao, Narikazu Boku, Yasuhide Yamada, Kensei Yamaguchi, Toshihiko Doi, Masahiro Goto, Junichiro Nasu, Tadamichi Denda, Yasuo Hamamoto, Atsuo Takashima, Haruhiko Fukuda, Atsushi Ohtsu, Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group
JournalJapanese journal of clinical oncology (Jpn J Clin Oncol) Vol. 43 Issue 10 Pg. 972-80 (Oct 2013) ISSN: 1465-3621 [Electronic] England
PMID24014884 (Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antimetabolites, Antineoplastic
  • Fluorouracil
  • Methotrexate
Topics
  • Adult
  • Aged
  • Anorexia (chemically induced)
  • Antimetabolites, Antineoplastic (administration & dosage, adverse effects)
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Drug Administration Schedule
  • Female
  • Fluorouracil (administration & dosage, adverse effects)
  • Humans
  • Infusions, Intravenous
  • Male
  • Methotrexate (administration & dosage, adverse effects)
  • Middle Aged
  • Multivariate Analysis
  • Neoplasm Staging
  • Neutropenia (chemically induced)
  • Odds Ratio
  • Peritoneal Neoplasms (drug therapy, secondary)
  • Stomach Neoplasms (drug therapy, pathology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: